Ardelyx (ARDX) Projected to Post Quarterly Earnings on Thursday

Ardelyx (NASDAQ:ARDX) will likely be announcing its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect Ardelyx to post earnings of $0.02 per share and revenue of $118.0430 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Ardelyx Stock Performance

Shares of ARDX stock opened at $7.26 on Thursday. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -31.56 and a beta of 0.57. The company has a debt-to-equity ratio of 1.31, a quick ratio of 4.11 and a current ratio of 4.41. Ardelyx has a one year low of $3.21 and a one year high of $8.40. The company’s 50-day moving average is $6.67 and its 200 day moving average is $6.00.

Insider Buying and Selling at Ardelyx

In related news, CEO Michael Raab sold 46,887 shares of the business’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $5.54, for a total transaction of $259,753.98. Following the completion of the transaction, the chief executive officer directly owned 1,455,363 shares in the company, valued at $8,062,711.02. The trade was a 3.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Laura A. Williams sold 50,000 shares of the business’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $6.98, for a total value of $349,000.00. Following the transaction, the insider directly owned 361,563 shares in the company, valued at $2,523,709.74. This trade represents a 12.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 114,868 shares of company stock valued at $708,369. 4.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ardelyx

Hedge funds and other institutional investors have recently bought and sold shares of the company. Deutsche Bank AG raised its stake in Ardelyx by 157.8% during the fourth quarter. Deutsche Bank AG now owns 500,195 shares of the biopharmaceutical company’s stock worth $2,916,000 after purchasing an additional 306,199 shares during the period. Cerity Partners LLC lifted its holdings in Ardelyx by 5.3% in the fourth quarter. Cerity Partners LLC now owns 59,359 shares of the biopharmaceutical company’s stock valued at $346,000 after acquiring an additional 2,972 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Ardelyx in the fourth quarter worth approximately $473,000. WINTON GROUP Ltd purchased a new stake in Ardelyx in the fourth quarter valued at $79,000. Finally, Vise Technologies Inc. acquired a new stake in shares of Ardelyx during the 4th quarter worth about $336,000. 58.92% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ARDX. BTIG Research reissued a “buy” rating and issued a $17.00 target price on shares of Ardelyx in a report on Thursday, January 29th. Piper Sandler upgraded shares of Ardelyx from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $10.00 to $16.00 in a research note on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Ardelyx in a research report on Wednesday, January 21st. TD Cowen reissued a “buy” rating on shares of Ardelyx in a report on Thursday, January 29th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $15.00 price target on shares of Ardelyx in a report on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $14.36.

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.